Publication: Treatment of mucormycosis in transplant patients: Role of surgery and of old and new antifungal agents
Issued Date
2016-08-01
Resource Type
ISSN
14736527
09517375
09517375
Other identifier(s)
2-s2.0-84969262556
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Opinion in Infectious Diseases. Vol.29, No.4 (2016), 340-345
Suggested Citation
Maria N. Chitasombat, Dimitrios P. Kontoyiannis Treatment of mucormycosis in transplant patients: Role of surgery and of old and new antifungal agents. Current Opinion in Infectious Diseases. Vol.29, No.4 (2016), 340-345. doi:10.1097/QCO.0000000000000277 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/41258
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Treatment of mucormycosis in transplant patients: Role of surgery and of old and new antifungal agents
Other Contributor(s)
Abstract
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. Purpose of review Mucormycosis is an opportunistic mold infection whose management is difficult, as there is a paucity of evidence-based data. We summarize the latest advances in diagnosis and management of mucormycosis in transplant recipients. Recent findings There is promise for improvement in nonculture-based diagnostics with new biomarkers of Mucorales DNA that can be used for early diagnosis, and monitoring of response. Antifungal treatment consists of high-dose lipid formulations of amphotericin B or isavuconazole as the first-line therapy and posaconazole as salvage therapy. The new, pharmacokinetically more reliable formulations of posaconazole (intravenous, extended-release tablets) are welcomed improvements. Yet, the role of combination therapy is still uncertain. Surgery had a significant role in selected cases, such as in patients with rhinosinusitis form of mucormycosis, which nowadays can be performed with minimal invasive technique. Summary Mucormycosis remain a life-threatening opportunistic mold infection among transplant patients. Early diagnosis, prompt treatment with effective antifungals in combination with surgery if feasible is essential. Immune adjunct therapy and improvement of early diagnostics are important areas for future research. There are good prospects of progress in diagnostics and management of mucormycosis in transplant patients.